H Laboratories

H-Laboratories (H-Labs) was a biotechnology company focused on cellular rejuvenation through epigenetic reprogramming to treat age-related diseases. As a subsidiary of Life Biosciences, the company was established to translate the research of Dr. David Sinclair into therapeutic applications, specifically focusing on resetting the "epigenetic clock" of cells. Their core technology utilized a combination of transcription factors—Oct4, Sox2, and Klf4 (OSK)—delivered via gene therapy to restore youthful function to aged or damaged tissues. The company's lead research demonstrated the ability to reverse vision loss in animal models of glaucoma and optic nerve damage. In 2019, H-Laboratories was fully consolidated into its parent company, Life Biosciences, to centralize the development of its longevity-focused pipeline.